Precision Biologics

New Data for Precision Biologics, Inc. PB-223 ADC against novel tumor-specific target on human cancers revealed at SITC 2026

Precision Biologics, Inc. CEO Philip M. Arlen, MD announces presentation of new data describing in-vivo efficacy of its novel tumor-specific…